Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Canopy Growth Co. stock logo
CGC
Canopy Growth
$1.71
-3.4%
$1.27
$0.77
$10.04
$314.41M0.795.82 million shs4.70 million shs
CervoMed Inc. stock logo
CRVO
CervoMed
$7.79
-1.0%
$9.18
$1.80
$22.57
$67.80M-0.231.33 million shs77,475 shs
Immutep Limited stock logo
IMMP
Immutep
$1.97
+2.1%
$1.74
$1.32
$3.05
$287.70M1.8218,349 shs133,702 shs
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
$7.90
+1.7%
$8.46
$7.10
$21.79
$299.83M0.04130,796 shs87,408 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Canopy Growth Co. stock logo
CGC
Canopy Growth
+4.12%-1.67%+32.09%+25.09%-79.13%
CervoMed Inc. stock logo
CRVO
CervoMed
-1.13%-7.52%-13.99%+256.11%-56.81%
Immutep Limited stock logo
IMMP
Immutep
-3.02%-0.52%+16.97%+1.58%-32.28%
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
+0.91%+1.04%-12.40%-35.14%-51.86%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Canopy Growth Co. stock logo
CGC
Canopy Growth
1.4685 of 5 stars
1.52.00.00.02.30.01.3
CervoMed Inc. stock logo
CRVO
CervoMed
3.4093 of 5 stars
4.43.00.00.02.91.70.6
Immutep Limited stock logo
IMMP
Immutep
1.2798 of 5 stars
3.51.00.00.02.50.00.0
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
2.9438 of 5 stars
3.62.00.00.03.31.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Canopy Growth Co. stock logo
CGC
Canopy Growth
1.00
Sell$2.0013.96% Upside
CervoMed Inc. stock logo
CRVO
CervoMed
2.89
Moderate Buy$27.63243.55% Upside
Immutep Limited stock logo
IMMP
Immutep
3.00
Buy$7.00250.88% Upside
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
3.25
Buy$25.67218.25% Upside

Current Analyst Ratings Breakdown

Latest CRVO, TRDA, CGC, and IMMP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/20/2025
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
5/13/2025
CervoMed Inc. stock logo
CRVO
CervoMed
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
5/12/2025
CervoMed Inc. stock logo
CRVO
CervoMed
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$14.00 ➝ $15.00
3/31/2025
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
3/26/2025
CervoMed Inc. stock logo
CRVO
CervoMed
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
3/18/2025
CervoMed Inc. stock logo
CRVO
CervoMed
Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $20.00
3/18/2025
CervoMed Inc. stock logo
CRVO
CervoMed
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$12.00 ➝ $21.00
3/17/2025
CervoMed Inc. stock logo
CRVO
CervoMed
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
3/13/2025
CervoMed Inc. stock logo
CRVO
CervoMed
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$15.00
3/13/2025
CervoMed Inc. stock logo
CRVO
CervoMed
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$14.00 ➝ $14.00
3/11/2025
CervoMed Inc. stock logo
CRVO
CervoMed
Brookline Capital Management
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Canopy Growth Co. stock logo
CGC
Canopy Growth
$276.75M1.17N/AN/A$2.72 per share0.65
CervoMed Inc. stock logo
CRVO
CervoMed
$7.14M9.80N/AN/A$1.30 per share6.19
Immutep Limited stock logo
IMMP
Immutep
$5.14M56.68N/AN/A$1.05 per share1.90
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
$172.22M1.78N/AN/A$7.26 per share1.11
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Canopy Growth Co. stock logo
CGC
Canopy Growth
-$487.23M-$3.80N/AN/AN/A-156.98%-56.52%-24.18%5/30/2025 (Confirmed)
CervoMed Inc. stock logo
CRVO
CervoMed
-$2.17M-$2.18N/AN/AN/A-118.68%-44.11%-39.81%8/8/2025 (Estimated)
Immutep Limited stock logo
IMMP
Immutep
-$28.01MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
-$6.68M$0.815.07N/AN/A25.53%16.11%10.39%8/12/2025 (Estimated)

Latest CRVO, TRDA, CGC, and IMMP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/30/2025Q4 2025
Canopy Growth Co. stock logo
CGC
Canopy Growth
-$0.28N/AN/AN/A$71.84 millionN/A
5/12/2025Q1 2025
CervoMed Inc. stock logo
CRVO
CervoMed
-$0.60-$0.56+$0.04-$0.56$1.70 million$1.92 million
5/8/2025Q1 2025
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
-$0.78-$0.42+$0.36-$0.42$10.98 million$8.75 million
3/17/2025Q4 2024
CervoMed Inc. stock logo
CRVO
CervoMed
-$0.67-$0.80-$0.13-$0.80$1.51 million$2.16 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Canopy Growth Co. stock logo
CGC
Canopy Growth
N/AN/AN/AN/AN/A
CervoMed Inc. stock logo
CRVO
CervoMed
N/AN/AN/AN/AN/A
Immutep Limited stock logo
IMMP
Immutep
N/AN/AN/AN/AN/A
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Canopy Growth Co. stock logo
CGC
Canopy Growth
0.74
3.52
2.58
CervoMed Inc. stock logo
CRVO
CervoMed
N/A
15.04
15.04
Immutep Limited stock logo
IMMP
Immutep
0.01
18.25
18.25
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
N/A
6.59
6.59

Institutional Ownership

CompanyInstitutional Ownership
Canopy Growth Co. stock logo
CGC
Canopy Growth
3.33%
CervoMed Inc. stock logo
CRVO
CervoMed
25.15%
Immutep Limited stock logo
IMMP
Immutep
2.32%
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
86.39%

Insider Ownership

CompanyInsider Ownership
Canopy Growth Co. stock logo
CGC
Canopy Growth
1.30%
CervoMed Inc. stock logo
CRVO
CervoMed
35.40%
Immutep Limited stock logo
IMMP
Immutep
3.07%
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
8.11%
CompanyEmployeesShares OutstandingFree FloatOptionable
Canopy Growth Co. stock logo
CGC
Canopy Growth
3,150183.87 million153.39 millionOptionable
CervoMed Inc. stock logo
CRVO
CervoMed
48.70 million3.93 millionNot Optionable
Immutep Limited stock logo
IMMP
Immutep
2,021146.04 million141.09 millionOptionable
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
11037.95 million34.58 millionOptionable

Recent News About These Companies

HC Wainwright Has Positive Forecast for TRDA Q2 Earnings
Q2 Earnings Forecast for TRDA Issued By HC Wainwright

New MarketBeat Followers Over Time

Media Sentiment Over Time

Canopy Growth stock logo

Canopy Growth NASDAQ:CGC

$1.71 -0.06 (-3.39%)
Closing price 04:00 PM Eastern
Extended Trading
$1.74 +0.03 (+1.46%)
As of 04:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

CervoMed stock logo

CervoMed NASDAQ:CRVO

$7.79 -0.08 (-1.02%)
Closing price 04:00 PM Eastern
Extended Trading
$7.77 -0.02 (-0.26%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Immutep stock logo

Immutep NASDAQ:IMMP

$1.97 +0.04 (+2.07%)
Closing price 04:00 PM Eastern
Extended Trading
$1.99 +0.02 (+0.96%)
As of 04:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Entrada Therapeutics stock logo

Entrada Therapeutics NASDAQ:TRDA

$7.90 +0.13 (+1.67%)
Closing price 04:00 PM Eastern
Extended Trading
$7.90 +0.00 (+0.06%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.